Incidence, Genetic Characteristics, and Outcomes of Paediatric Cardiomyopathy in a National Cohort (2003–2025) - Takeaways - MDSpire

Incidence, Genetic Characteristics, and Outcomes of Paediatric Cardiomyopathy in a National Cohort (2003–2025)

  • By

  • Scott Kendall

  • Shannon Scott

  • Peter McClung

  • Joy McCance

  • Nawab Ali

  • Gillian Rea

  • William Wright

  • Jane Murray

  • Alison Muir

  • Martin Dempster

  • Terrence Prendiville

  • Pascal McKeown

  • Frank Casey

  • June 26, 2026

  • 0 min

Share

  • 1

    Pediatric cardiomyopathy is a rare condition with diverse presentations, primarily including dilated and hypertrophic cardiomyopathy.

  • 2

    The incidence of pediatric cardiomyopathy is estimated at around 1 in 100,000 children, with DCM being the leading cause of pediatric heart transplantation.

  • 3

    Eighty-four children were diagnosed with various types of pediatric cardiomyopathy, with a median age at diagnosis of 2 years.

  • 4

    Sixty-two children were included in incidence analyses, revealing a mean annual incidence of 0.9 per 100,000 children for DCM and HCM.

  • 5

    Genetic testing identified pathogenic variants in 61% of patients, with the majority being sarcomeric variants.

Original Source(s)

Incidence, Genetic Characteristics, and Outcomes of Paediatric Cardiomyopathy in a National Cohort (2003–2025)

  • by Scott Kendall, Shannon Scott, Peter McClung, Joy McCance, Nawab Ali, Gillian Rea, William Wright, Jane Murray, Alison Muir, Martin Dempster, Terrence Prendiville, Pascal McKeown, Frank Casey

  • June 26, 2026

Related Content

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Model-guided medicine for early diagnosis of transthyretin-associated cardiac amyloidosis using multimodal data integration and standardized interoperable models (the CRONOS-ATTR study)